"Setting squirrel traps while elephants stomp you into pancakes."  Dr. Jones addresses questions about FSHD diagnostics and stem cells.

"Never planned anything in my life."  Drs. Peter Jones and Charis Himeda talk more small molecule and discusses news of the week as it relates to FSHD

"Hey wanna s'more?"... "S'more what?"... "No, do you wanna s'more?"... "I haven't had anything yet, so how can I have s'more of nothing?".... "You're KILLIN' ME SMALLS!"  Drs. Peter Jones and Charis Himeda talk small molecule drug discovery pathways for FSHD.

Today we answer listener questions about FSHD research testing and AAV gene therapy.

"They've done studies you know -- 60% of the time it works all the time."... "That doesn't make any sense."  We discuss the different types of antisense oligonucleotide (AON/ASO) technologies and how these can be used therapeutically for FSHD.

"What we have here is failure to communicate..."  We discuss more on gene therapy viral vectors and answer a listener question about melatonin supplementation for FSHD

"So much time so little to do.  Wait a minute.  Strike that.  Reverse it."  Drs. Charis Himeda and Peter Jones go back over gene therapy technology for FSHD, including some of the remaining hurdles, and how technology has advanced over the years to meet the challenges.

Dr. Jones answers some of your questions from the week and reviews recent advances in science that relate to FSHD

Drs. Peter and Takako Jones discuss the ACE-083 trial and the basis of myostatin inhibition for FSHD, and go through the data showing that berberine, despite proof-of-concept studies showing it to be an inhibitor of DUX4 expression, is highly unlikely to be an effective treatment for FSHD.

Dr. Peter Jones catches you up on the week in FSHD.